Viemed Healthcare Faces Rising Compliance Costs After Losing Special Reporting Status

Viemed Healthcare US (VMD) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Viemed Healthcare US faces increased costs and demands on management after losing its status as a smaller reporting company and emerging growth company. As of June 30, 2023, the company became subject to expanded disclosure requirements, including providing an auditor attestation of internal control, audited financial statements for three fiscal years, and increased executive compensation disclosures. These changes could lead to higher legal and financial compliance costs, divert attention from operational matters, and potentially affect the market price of its common shares if compliance with the new requirements is not timely. Additionally, the company risks sanctions or investigations from regulatory authorities if it fails to meet these obligations.

The average VMD stock price target is $15.00, implying 92.31% upside potential.

To learn more about Viemed Healthcare US’ risk factors, click here.